A Law That Took Effect Before Anyone Knew How to Apply It

On 30 July 2026, a provision buried inside Germany's latest statutory health insurance cost-control package came into force — and roughly 65,000 patients who had been receiving cannabis therapy through their public insurer woke up to a sharply altered reality. Dried cannabis flower was removed from the special reimbursement entitlement overnight, with no transitional protection for patients already mid-treatment. A second measure required that any new prescription of extracts, dronabinol, or nabilone be preceded by a mandatory six-month trial of an approved cannabis-based finished medicine.

The law, published unchanged into the Federal Gazette on 29 July following a vote on 10 July, is already the subject of a constitutional complaint filed with Germany's Federal Constitutional Court. What makes the situation particularly acute is not just the political fight — it is that the practical mechanics of implementation remain unresolved even as the law is nominally in effect.

A Mandatory Trial With Nowhere to Turn

Germany currently has four approved cannabis-based finished medicines: Sativex, licensed for multiple sclerosis spasticity; Epidyolex, for specific epilepsy syndromes; Canemes, for chemotherapy-induced nausea; and Exilby, for chronic back pain. Their licences are narrow. For the vast majority of conditions under which patients have been prescribed cannabis — chronic pain, PTSD, sleep disorders, and a range of neurological conditions — there is no approved on-label finished medicine to serve as a mandatory first step.

This creates a structural contradiction at the heart of the law. If a six-month trial is compulsory but the only eligible medicines cover a fraction of actual patient diagnoses, then any meaningful application of the rule would require widespread off-label prescribing — a route that statutory insurers reimburse only in exceptional circumstances and with significant bureaucratic hurdles.

Pharmacies and medical cannabis distributors are now pressing insurers and the statutory medical review service for concrete answers: when can the six-month requirement be waived for palliative care patients? How are paediatric patients, swallowing disorders, or tube-feeding cases handled? What documentation will be required? As of publication, no formal guidance has been issued.

The Arbeitsgemeinschaft Cannabis als Medizin (ACM), one of Germany's longest-standing medical cannabis advocacy bodies, announced in mid-July that it would bring a constitutional complaint before the Federal Constitutional Court, to be filed by Professor Oliver Tolmein, a lawyer with an established record in cannabis-related legal cases. The case will be supported by the Deutscher Hanfverband and funded through a dedicated public donation account.

The ACM's chairman, Dr Franjo Grotenhermen, was direct in his assessment: the legislation, he wrote, "wrongly assumes that cannabis medicines are interchangeable" — an assumption he argued was clinically unfounded.

The Bund Deutscher Cannabis-Patienten (BDCan) took a separate route, writing directly to Federal President Frank-Walter Steinmeier to request a constitutional review under Article 82(1) of the Basic Law before the law was signed into force. The association's chair, Daniela Joachim, framed the stakes plainly: "Seriously ill people must not lose their proven therapy overnight. This is about security of supply, and about not interrupting ongoing treatments unnecessarily."

The pharmaceutical cannabinoid industry body BPC has called the provisions a "double burden" on seriously ill patients, and is calling for the blanket flower exclusion to be withdrawn and for the finished-medicine priority rule to apply only where an approved preparation is actually available and deliverable.

The Broader Signal for European Medical Markets

Germany's medical cannabis framework had been closely watched across Europe after the country moved to partially liberalise access in 2024. The speed with which cost pressures have now reshaped that framework — stripping a core reimbursement category with no transition period and leaving implementation guidance to catch up after the fact — offers a cautionary lesson for other markets building out medical access programmes.

Malta's own regulated framework, overseen by the Authority on the Responsible Use of Cannabis (ARUC), operates on a different model, with no equivalent statutory insurance reimbursement for cannabis prescriptions currently in place. But the German episode will be of interest to those engaged in the ongoing discussion about whether and how cannabis therapies could eventually sit within Malta's public healthcare system. The German experience suggests that the policy architecture underpinning access — not just the initial legalisation act — is where patient security is ultimately determined.

For now, the immediate question is whether Germany's Federal Constitutional Court will intervene quickly enough to matter. With 65,000 patients in established therapy and no clear transitional pathway, the gap between the law as written and the law as it can realistically be applied may prove to be the strongest argument the patient groups have.

Sources

'Everything in Our Power': German Patient Groups Fight to Overturn Cannabis Insurance Cuts — Business of Cannabis. https://businessofcannabis.com/everything-in-our-power-german-patient-groups-fight-to-overturn-cannabis-insurance-cuts/

Featured image: Photo by Osviel Rodriguez Valdés on Pexels

Share this article
The link has been copied!